Ginkgo Bioworks

All of the founders of Ginkgo Bioworks created an affiliate, Stegodon Corporation, to provide and assume certain debt notes to Amyris while keeping the debt off Ginkgo Bioworks' books. Amyris' failure to pay debts at certain maturity dates has resulted in Stegodon Corporation receiving certain patents from the company as collateral, several of which it has paid to upkeep with the U.S. Patent and Trademark Office, proving that Stegodon Corporation is actively managed. Ginkgo Bioworks hasn't commented publicly on the existence of Stegodon Corporation or the affiliate's purpose. On June 29th, 2018, Amyris secured a $35 million loan to repay all amounts owed to Stegodon Corporation.

On March 20th, 2018, Ginkgo Bioworks announced it had finalized a previously-announced joint venture with the agriscience business of Bayer, towhich will be called Joyn Bio. The joint venture will focus on designing soil microbes to improve the root system microbiomes of agricultural crops, specifically providing nitrogen fixation to reduce the need for synthetic fertilizer applications. Joyn Bio is similar to the $600 million joint venture between Monsanto and Novozymes called the BioAg Alliance, which commercialized its first products in December 2016 after conducting years of field testing. Monsanto is now a part of Bayer.

On March 20th, 2018, the German company Bayer and its crop science division announced they will be starting a new company called Joyn Bio that will focus on designing soil microbes to improve the health of root system microbiomes of agricultural crops.

On March 20th, 2018, Ginkgo Bioworks announced it had finalized a previously-announced joint venture with the agriscience business of Bayer to be called Joyn Bio. The joint venture will focus on designing soil microbes to improve the root system microbiomes of agricultural crops, specifically providing nitrogen fixation to reduce the need for synthetic fertilizer applications. Joyn Bio is similar to the $600 million joint venture between Monsanto and Novozymes called the BioAg Alliance, which commercialized its first products in December 2016 after conducting years of field testing. Monsanto is now a part of Bayer.

Ginkgo Bioworks was founded in 2009 by scientists at MIT and is located in Boston, Massachusetts. Ginkgo Bioworks is a biotechnology company that focuses on building designer organisms, and is the self proclaimed "Organism Company". They design custom microbes in their own synthetic biology foundries. The foundries consist of a variety of software and hardware tools that allow for rapid prototyping, and manufacturing of microorganisms in high volumes. Their custom microbes are engineered to produce products and services that meet their clients needs such as chemical intermediates, flavors, fragrances, and more.

Ginkgo Bioworks was founded in 2009 by scientists at MIT and is located in Boston, Massachusetts. Ginkgo Bioworks is an analytics company that designs organisms for customers in a range of industries. It is the self-proclaimed "Organism Company".

Ginkgo Bioworks designs microbes in analytical labs it calls synthetic biology foundries, which comprise software and hardware tools that allow for rapid prototyping and high-throughput screening. Several publicly-stated products include chemical intermediates, flavors, and fragrances; as well as microbes that provide health benefits to the human gut microbiome and agricultural crop root microbiomes.

Ginkgo Bioworks specializes in creating tools for improving cultured ingredients, high-throughput strain improvement, and enzymes design. Cultured ingredients are made by yeast fermentation, and the yeast can be made to produce compounds for use as flavors, fragrances, food ingredients, cosmetics, and more.

Ginkgo Bioworks specializes in creating tools for improving cultured ingredients, high throughput strain improvement, and enzymes design. Cultured ingredients are made by yeast fermentation, and the yeast can be made to produce compounds for perfumes, food, cosmetics, and much more. High throughput strain improvement is the next step after figuring out how to make cultured ingredients. Strain improvement seeks to increase efficiency, reduces cost, and improve the sustainability of of products made by custom organisms. Enzyme design looks for ways to either use existing enzymes for other purposes or looks for ways the make enzymes do their job better. Enzymes act as catalysts that speed up biochemical reactions. Examples of the industrial use of enzymes include cheesemaking, pharmaceutical production, and clothing manufacturing. Yeast fermentation to produce perfume scents.

BioworksS1 was the worldsworld's first organism foundry capable of complete automatingautomation of organism strain engineering. The foundry can perform up to 15,000 automated lab tasks per month allowing genetic engineers at Ginkgo Bioworks to test thousands of new organism designs every month without the need to perform the majority of repetitive lab work.

BioworksS2 is an upgraded version of BIOWORKS1 that is twice as big. It's able to produceprovides a 6X productivity improvement on the original BioworksS1 foundry through more efficient integration and miniaturization of equipment.

In its early years, the biotech company was supported primarily through governments grants. Working on a variety of projects with different government agencies, such as the national science foundation and Defense Advanced Research Projects Agency (DARPA), before gaining access to venture capital funding in the summer of 2014.

All of the founders of Ginkgo Bioworks created an affiliate, Stegodon Corporation, to provide and assume certain debt notes to Amyris while keeping the debt off Ginkgo Bioworks' books. Amyris' failure to pay debts at certain maturity dates has resulted in Stegodon Corporation receiving certain patents from the company as collateral, several of which it has paid to upkeep with the U.S. Patent and Trademark Office, proving that Stegodon Corporation is actively managed. Ginkgo Bioworks hasn't commented publicly on the existence of Stegodon Corporation or the affiliate's purpose.

On September 23rd, 2016, Ginkgo Bioworks announced they will bea workingpartnership with Archer Daniels Midland Company (ADM) to design organisms capable of producing cultured ingredients for use in agricultural processing and food ingredient industries. ADM hopes to help Ginkgo Bioworks create new organisms that reduce cost and increase the sustainability of their agricultural processing and food ingredient business. ADM plans on using Ginkgo Bioworks for solving problems faced by theirits customers through providing novel ingredient production and formulation processes.

On March 20th, 2018, the German company Bayer and its crop science division announced they will be starting a new company called Joyn Bio that will focus on designing soil microbes to improve the health of root system microbiomes of agricultural crops.

On September 22nd, 2016, Ginkgo Bioworks announced on September 22, 2016 that they will being partneringa uppartnership with Cargill to help them improve their bio-industrialindustrial fermentation processes.

The partnershipOn betweenSeptember Genomatica29th, and2016, GinkgoGinko Bioworks was announced ona Septemberpartnership 29th,with 2016Genomatica. The companies will be focusing on scaling and commercializing the intermediate and speciality chemical production of organisms made by Ginkgo Bioworks. Genomatica designs and improves industrial process of bio-manufacturing by creating economic and technical solutions to problems faced within the bio-manufacturing industry. The goal of this partnership is for both companies to work together create a unified offer for the market that provides organism design and high volume manufacturing capacity.

On October 19th, 2016, Ginkgo Bioworks becameannounced partnersa partnership with Prospect Bio. Prospect Bio and Ginkgo Bioworks are working together to create a new biosensor that willto improve the speed and lower the cost of organism prototyping for new strain development. The biosensor under development will make the process of organism screening (testing for a desired trait) faster. Organism screening is one of the slowest processes of the design, build, test system Ginkgo Bioworks uses for organism development. Normally, each organism created by Ginkgo Bioworks has to be screened individually. A biosensor allows for the screening of many organisms at one time. Ginkgo Bioworks is hoping for a forty-fold decrease in the cost of screening and increase the speed of creating commercial ready organisms.

On December 8th, 2017, Ginkgo Bioworks and Synlogic announced a collaboration to engineer microbes for probiotic and gut-microbiome-based medicines.

Ginkgo Bioworks CEO Jason Kelly said of acquiring Gen9, "Our mission is to make biology easier to engineer and through that to enable our customers to grow better products. Having Gen9’s synthesis and assembly technology available to our customers is a valuable addition to our foundries, allowing us to further speed up the process of organism design".

All of the founders of Ginkgo Bioworks created an affiliate, Stegodon Corporation, to provide and assume certain debt notes to Amyris while keeping the debt off Ginkgo Bioworks' books. Amyris' failure to pay debts at certain maturity dates has resulted in Stegodon Corporation receiving certain patents from the company as collateral, several of which it has paid to upkeep with the U.S. Patent and Trademark Office. Ginkgo Bioworks hasn't commented publicly on the existence of Stegodon Corporation.

On December 8th, 2017 Ginkgo Bioworks and Synlogic announced a collaboration to engineer microbes for probiotic and gut-microbiome-based medicines.

All of the founders of Ginkgo Bioworks created an affiliate, Stegodon Corporation, to provide and assume certain debt notes to Amyris while keeping the debt off Ginkgo Biowork'sBioworks' books. Amyris' failure to pay debts at certain maturity dates has resulted in Stegodon Corporation receiving certain patents from the company as collateral, several of which it has paid to upkeep with the U.S. Patent and Trademark Office.

All of the founders of Ginkgo Bioworks created an affiliate, Stegodon Corporation, to provide and assume certain debt notes to Amyris while keeping the debt off Ginkgo Biowork's books. Amyris' failure to pay debts at certain maturity dates has resulted in Stegodon Corporation receiving certain patents from the company as collateral, several of which it has paid to upkeep with the U.S. Patent and Trademark Office.

Ginkgo Bioworks was founded in 2009 by scientists at MIT and is located in Boston, Massachusetts. Ginkgo Bioworks is a biotechnology company that focuses on building designer organisms, and is the self proclaimed "Organism Company". They design custom microbes in their own synthetic biology foundries. The foundries consist of a variety of software and hardware tools that allow for rapid prototyping, and manufacturing of microorganisms in high volumes. Their custom microbes are engineered to produce products and services that meet their clients needs such as chemical intermediates, food additivesflavors, scentsfragrances, and much more.

On June 29th, 2016 Ginkgo Bioworks and Amyris entered into a collaboration agreement and announced their intention to partner to commercialize up to 70 cultured ingredients. The partnership was entered into in November 2017. Ginkgo Bioworks agreed to pay up to $20 million in technology access fees to Amyris. It paid $15 million upfront in 2016, but disputes resulted in the final $5 million never being paid. The pair continue to collaborate on "limited research and development", although Amyris hasn't recorded revenue from Gingko Bioworks since the initial upfront payment in 2016.

All of the founders of Ginkgo Bioworks created an affiliate, Stegodon Corporation, to provide and assume certain debt notes to Amyris. Amyris' failure to pay debts at certain maturity dates has resulted in Stegodon Corporation receiving certain patents from the company as collateral, several of which it has paid to upkeep with the U.S. Patent and Trademark Office.